Thioredoxin Prevents Loss of UCP2 in Hyperoxia via MKK4-p38 MAPK-PGC1α Signaling and Limits Oxygen Toxicity

Administration of high concentrations of oxygen (hyperoxia) is one of few available options to treat acute hypoxemia-related respiratory failure, as seen in the current coronavirus disease (COVID-19) pandemic. Although hyperoxia can cause acute lung injury through increased production of superoxide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of respiratory cell and molecular biology 2022-03, Vol.66 (3), p.323-336
Hauptverfasser:	Raghavan, Somasundaram, Kundumani-Sridharan, Venkatesh, Kumar, Sudhir, White, Carl W, Das, Kumuda C
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cell Line Coronaviruses COVID-19 - metabolism COVID-19 - therapy Humans Hyperoxia Hyperoxia - metabolism Hypoxemia Lung - cytology Lung - metabolism Lung diseases MAP kinase MAP Kinase Kinase 4 - genetics MAP Kinase Kinase 4 - metabolism Mice Mice, Inbred C57BL Mice, Knockout Mice, Transgenic Mitochondrial uncoupling protein 2 Original Research Oxygen Oxygen - metabolism Oxygen - toxicity p38 Mitogen-Activated Protein Kinases - genetics p38 Mitogen-Activated Protein Kinases - metabolism Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - genetics Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism Phosphorylation Respiratory diseases Respiratory failure Signal Transduction Superoxide anions Superoxides - metabolism Thioredoxin Thioredoxins - genetics Thioredoxins - metabolism Thioredoxins - pharmacology Toxicity Uncoupling Protein 2 - genetics Uncoupling Protein 2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!